Literature DB >> 2460022

Multiple sclerosis: involvement of interferons in lesion pathogenesis.

U Traugott1, P Lebon.   

Abstract

To investigate a possible role of interferons (IFNs) in lesion pathogenesis, central nervous system tissue from multiple sclerosis patients and control subjects was stained by immunocytochemical techniques in combination with monoclonal antibodies or polyclonal antisera for the demonstration of IFN-alpha, IFN-beta, and IFN-gamma. The results were correlated to lesion activity, to the presence of class I and class II major histocompatibility antigen-positive astrocytes, and to the composition of cellular infiltrates. IFNs were detectable in active but not in inactive chronic multiple sclerosis lesions. In acute multiple sclerosis plaques, all three types of IFN were widely distributed on glial elements and infiltrating cells. In active chronic multiple sclerosis, labeling of cells for IFN-alpha, IFN-beta, and IFN-gamma was most pronounced at the lesion edge and displayed distinct distribution patterns. Overall, IFN-gamma was more common than IFN-alpha and IFN-beta and was predominantly found on astrocytes. IFN-alpha was detectable mainly on macrophages. Distribution of IFN-beta partially overlapped with that of IFN-gamma and IFN-alpha, in that it was present on some astrocytes and on some macrophages. IFNs were rare in normal white matter remote from lesions and in the gliotic lesion center. Ia antigen and human leukocyte antigen ABC on astrocytes were distributed similarly to IFN-gamma and IFN-beta, respectively. These findings indicate that IFN-gamma may play a role in active lesion growth in multiple sclerosis, whereas IFN-alpha and IFN-beta may exert some local immunosuppressive effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460022     DOI: 10.1002/ana.410240211

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  43 in total

Review 1.  Antigen specific immunotherapy of multiple sclerosis.

Authors:  L Steinman; P Conlon
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

Review 2.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  Short small-interfering RNAs produce interferon-α-mediated analgesia.

Authors:  P H Tan; Y J Gao; T Berta; Z Z Xu; R R Ji
Journal:  Br J Anaesth       Date:  2012-02-03       Impact factor: 9.166

4.  Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis.

Authors:  Sevim Karakas Celik; Zehra Safi Öz; Ahmet Dursun; Aysun Unal; Ufuk Emre; Salih Cicek; Fatih Mehmet Keni
Journal:  Mol Biol Rep       Date:  2014-01-09       Impact factor: 2.316

Review 5.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

6.  Neurons produce type I interferon during viral encephalitis.

Authors:  Sophie Delhaye; Sophie Paul; Gjon Blakqori; Muriel Minet; Friedemann Weber; Peter Staeheli; Thomas Michiels
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

7.  Identification of interferon-resistant subpopulations in several strains of measles virus: positive selection by growth of the virus in brain tissue.

Authors:  D R Carrigan; K K Knox
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

8.  Localization of interferon-gamma and Ia-antigen in T cell line-mediated experimental autoimmune encephalomyelitis.

Authors:  G Stoll; S Müller; B Schmidt; P van der Meide; S Jung; K V Toyka; H P Hartung
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

9.  KIR2DL4-HLAG interaction at human NK cell-oligodendrocyte interfaces regulates IFN-γ-mediated effects.

Authors:  P P Banerjee; L Pang; S S Soldan; S M Miah; A Eisenberg; S Maru; A Waldman; E A Smith; Y Rosenberg-Hasson; D Hirschberg; A Smith; D V Ablashi; K S Campbell; J S Orange
Journal:  Mol Immunol       Date:  2018-11-24       Impact factor: 4.407

Review 10.  Type I interferon in organ-targeted autoimmune and inflammatory diseases.

Authors:  Mary K Crow
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.